B Svendsen1,2, N Grytten3, L Bø3,4, H Aarseth5, T Smedal3,6, K-M Myhr4,5. 1. Department of Neurology, Norwegian Multiple Sclerosis Competence Centre, Haukeland University Hospital, PB 1400, 5021, Bergen, Norway. bjoern.o.svendsen@gmail.com. 2. Department of Business and Science, Norwegian School of Economics, Bergen, Norway. bjoern.o.svendsen@gmail.com. 3. Department of Neurology, Norwegian Multiple Sclerosis Competence Centre, Haukeland University Hospital, PB 1400, 5021, Bergen, Norway. 4. Department of Clinical Medicine, University of Bergen, Bergen, Norway. 5. Department of Neurology, Norwegian MS Registry and Biobank, Haukeland University Hospital, Bergen, Norway. 6. Department of Physiotherapy, Haukeland University Hospital, Bergen, Norway.
Abstract
BACKGROUND: Multiple sclerosis (MS) imposes high economic costs on society, but the patients and their families have to bear some of these costs. OBJECTIVE: We aimed to estimate the magnitude of these economic costs in Norway. METHOD: We collected data through a postal questionnaire survey targeting 922 MS patients in Hordaland County, western Norway, in 2013-2014; 546 agreed to participate and were included. The questionnaire included clinical and demographic characteristics, volume and cost of MS-related resource use, work participation, income, government financial support, and disability status. RESULTS: The mean annual total economic costs for the patients and their families were €11,603. Indirect costs accounted for 66% and were lower for women than for men. The direct costs were nearly identical for men and women. The costs increased up to Expanded Disability Status Scale score 6 except for steps between 3 and 4 where it remained nearly constant. The costs reduced from EDSS 6 to 8, and increased from 8 to 9. Lifetime costs ranged from €24,897 to €70,021 for patients with late disease onset and slow progression, and between €441,934 and €574,860 for patients with early onset and rapid progression. CONCLUSION: The economic costs of MS impose a heavy burden on the patients and their families. Supplementing the information on the cost of MS to society, our finding should be included as background information in decisions on reimbursing and allocating public resources for the well-being of MS patients and their families.
BACKGROUND:Multiple sclerosis (MS) imposes high economic costs on society, but the patients and their families have to bear some of these costs. OBJECTIVE: We aimed to estimate the magnitude of these economic costs in Norway. METHOD: We collected data through a postal questionnaire survey targeting 922 MS patients in Hordaland County, western Norway, in 2013-2014; 546 agreed to participate and were included. The questionnaire included clinical and demographic characteristics, volume and cost of MS-related resource use, work participation, income, government financial support, and disability status. RESULTS: The mean annual total economic costs for the patients and their families were €11,603. Indirect costs accounted for 66% and were lower for women than for men. The direct costs were nearly identical for men and women. The costs increased up to Expanded Disability Status Scale score 6 except for steps between 3 and 4 where it remained nearly constant. The costs reduced from EDSS 6 to 8, and increased from 8 to 9. Lifetime costs ranged from €24,897 to €70,021 for patients with late disease onset and slow progression, and between €441,934 and €574,860 for patients with early onset and rapid progression. CONCLUSION: The economic costs of MS impose a heavy burden on the patients and their families. Supplementing the information on the cost of MS to society, our finding should be included as background information in decisions on reimbursing and allocating public resources for the well-being of MS patients and their families.
Entities:
Keywords:
Costs; EDSS; Global MSSS; MS; Norway; Patient perspective
Authors: R H S R Roxburgh; S R Seaman; T Masterman; A E Hensiek; S J Sawcer; S Vukusic; I Achiti; C Confavreux; M Coustans; E le Page; G Edan; G V McDonnell; S Hawkins; M Trojano; M Liguori; E Cocco; M G Marrosu; F Tesser; M A Leone; A Weber; F Zipp; B Miterski; J T Epplen; A Oturai; P Soelberg Sørensen; E G Celius; N Téllez Lara; X Montalban; P Villoslada; A M Silva; M Marta; I Leite; B Dubois; J Rubio; H Butzkueven; T Kilpatrick; M P Mycko; K W Selmaj; M E Rio; M Sá; G Salemi; G Savettieri; J Hillert; D A S Compston Journal: Neurology Date: 2005-04-12 Impact factor: 9.910
Authors: Michael Wiberg; Emilie Friberg; Magnus Stenbeck; Kristina Alexanderson; Anders Norlund; Jan Hillert; Petter Tinghög Journal: Mult Scler Date: 2015-02-19 Impact factor: 6.312
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422